ANI Pharmaceuticals (ANIP) Hisse Özeti
Bir biyofarmasötik şirketi olan ANI Pharmaceuticals, Inc. Amerika Birleşik Devletleri'nde ve uluslararası alanda markalı ve jenerik farmasötik ürünler geliştirmekte, üretmekte ve pazarlamaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 5/6 |
| Gelecekteki Büyüme | 4/6 |
| Geçmiş Performans | 2/6 |
| Finansal Sağlık | 4/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
ANIP Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ANI Pharmaceuticals, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$83.78 |
| 52 Haftanın En Yüksek Seviyesi | US$99.50 |
| 52 Haftanın En Düşük Seviyesi | US$62.61 |
| Beta | 0.43 |
| 1 Aylık Değişim | 3.18% |
| 3 Aylık Değişim | 6.92% |
| 1 Yıllık Değişim | 26.75% |
| 3 Yıllık Değişim | 65.74% |
| 5 Yıllık Değişim | 154.03% |
| Halka arzdan bu yana değişim | 1,229.84% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jul 01
ANIP: Higher Long Run Margins Will Support Bullish Case Ahead
Analysts have raised their price target for ANI Pharmaceuticals from $90.00 to $100.00, citing updated assumptions related to revenue growth, profit margins, and a slightly higher future P/E multiple. What’s in the News for ANI Pharmaceuticals ANI Pharmaceuticals announced a voluntary, firm initiated Class II recall of Estradiol Gel 0.1% packets after some containers were found empty or partially full, covering 3,964 cartons from Lot M251109, with distribution nationwide in the USA, according to a US Food and Drug Administration enforcement report.Seeking Alpha • Jun 26
ANI Pharmaceuticals: Rare Disease Growth At A Generics Multiple
Summary ANI Pharmaceuticals is rated a speculative buy, with the investment thesis centered on Cortrophin Gel's rare disease revenue growth and transformation. Management guides to $540M-$575M Cortrophin revenue in 2026, making rare disease close to 60% of total revenue and supporting a re-rating. A $108 fair value is based on 9x 2026 adjusted EBITDA, offering ~30% upside if Cortrophin growth and gout expansion materialize as guided. Key risks include payer dynamics, Cortrophin concentration, and execution of the gout expansion, with current low multiples justified only if growth falters. Read the full article on Seeking AlphaAnaliz Makalesi • Jun 21
ANI Pharmaceuticals (ANIP) Stock Could Be 29.5% Below Fair Value After Recent Pullback
ANI Pharmaceuticals (ANIP) has drawn investor interest after recent share price moves, with the stock closing at US$79.49 and showing mixed short term performance alongside longer term total returns. See our latest analysis for ANI Pharmaceuticals. The recent dip in ANI Pharmaceuticals’ share price, including a 1-month share price return of 3.9% down from its recent high, contrasts with a 1-year total shareholder return of 21.25%. This suggests longer term momentum has still been positive...
Anlatı Güncellemesi • Jun 17
ANIP: Buyback And Stronger Cash Generation Will Support Future Earnings Power
The analyst price target for ANI Pharmaceuticals has been adjusted from $109.88 to $112.71. Analysts attribute the change to updated fair value estimates and a slightly higher assumed future P/E multiple as key drivers.Recent updates
Anlatı Güncellemesi • Jul 01
ANIP: Higher Long Run Margins Will Support Bullish Case Ahead
Analysts have raised their price target for ANI Pharmaceuticals from $90.00 to $100.00, citing updated assumptions related to revenue growth, profit margins, and a slightly higher future P/E multiple. What’s in the News for ANI Pharmaceuticals ANI Pharmaceuticals announced a voluntary, firm initiated Class II recall of Estradiol Gel 0.1% packets after some containers were found empty or partially full, covering 3,964 cartons from Lot M251109, with distribution nationwide in the USA, according to a US Food and Drug Administration enforcement report.Seeking Alpha • Jun 26
ANI Pharmaceuticals: Rare Disease Growth At A Generics Multiple
Summary ANI Pharmaceuticals is rated a speculative buy, with the investment thesis centered on Cortrophin Gel's rare disease revenue growth and transformation. Management guides to $540M-$575M Cortrophin revenue in 2026, making rare disease close to 60% of total revenue and supporting a re-rating. A $108 fair value is based on 9x 2026 adjusted EBITDA, offering ~30% upside if Cortrophin growth and gout expansion materialize as guided. Key risks include payer dynamics, Cortrophin concentration, and execution of the gout expansion, with current low multiples justified only if growth falters. Read the full article on Seeking AlphaAnaliz Makalesi • Jun 21
ANI Pharmaceuticals (ANIP) Stock Could Be 29.5% Below Fair Value After Recent Pullback
ANI Pharmaceuticals (ANIP) has drawn investor interest after recent share price moves, with the stock closing at US$79.49 and showing mixed short term performance alongside longer term total returns. See our latest analysis for ANI Pharmaceuticals. The recent dip in ANI Pharmaceuticals’ share price, including a 1-month share price return of 3.9% down from its recent high, contrasts with a 1-year total shareholder return of 21.25%. This suggests longer term momentum has still been positive...Anlatı Güncellemesi • Jun 17
ANIP: Buyback And Stronger Cash Generation Will Support Future Earnings Power
The analyst price target for ANI Pharmaceuticals has been adjusted from $109.88 to $112.71. Analysts attribute the change to updated fair value estimates and a slightly higher assumed future P/E multiple as key drivers.Anlatı Güncellemesi • Jun 02
ANIP: Raised 2026 Outlook And Buyback Will Support Stronger Earnings Power
Analysts have trimmed their price target on ANI Pharmaceuticals by $0.75 to $109.88, reflecting updated views on fair value, a slightly higher discount rate, moderated revenue growth assumptions, a higher projected profit margin, and a lower future P/E multiple. What's in the News Q1 2026 results: Total net revenues of US$237.5 million, up 20.5% year over year, with Rare Disease products such as Cortrophin Gel and ILUVIEN as key contributors.Anlatı Güncellemesi • May 13
ANIP: Higher Margin Outlook Will Support Bullish Case Over Coming Years
Analysts have maintained their $90.00 price target on ANI Pharmaceuticals, citing updated assumptions around slightly different revenue growth, a higher profit margin, and a lower future P/E as the main factors supporting the unchanged view. What's in the News Raised full year 2026 revenue guidance to a range of US$1.08b to US$1.14b, compared with prior guidance of US$1.055b to US$1.115b (company guidance).Anlatı Güncellemesi • Apr 24
ANIP: 2026 Revenue Guidance And New Launches Will Support Upside Potential
Analysts have kept their $90.00 price target for ANI Pharmaceuticals unchanged, citing relatively steady assumptions for revenue growth, profit margins, and future P/E as the basis for this view. What's in the News Launched Pimozide Tablets 1 mg and 2 mg, a generic version of Orap, with U.S. annual sales for the category of about US$3.1 million based on February 2026 IQVIA data (Key Developments).Anlatı Güncellemesi • Apr 08
ANIP: 2026 Revenue Guidance Will Test Confidence In Margin Assumptions
Analysts lifted their price target on ANI Pharmaceuticals by $9, reflecting updated expectations around revenue growth, profit margin, and future P/E assumptions highlighted in recent Street research. Analyst Commentary While the updated target reflects renewed confidence in revenue and margin assumptions, bearish analysts are still flagging several areas where expectations may be running ahead of what the company can reasonably deliver.Anlatı Güncellemesi • Mar 25
ANIP: Higher 2026 Guidance And Margin Outlook Will Support Stronger Earnings Power
Analysts have raised their price target on ANI Pharmaceuticals by $9 to $110.63, citing updated expectations for revenue growth, profit margins, and a lower future P/E assumption. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as better aligned with updated expectations for revenue and margin performance, which they factor into their cash flow and earnings models.Anlatı Güncellemesi • Mar 11
ANIP: Higher 2026 Guidance Will Test Assumed Margin Expansion
Analysts have lifted their price target on ANI Pharmaceuticals by $9, citing updated assumptions for revenue growth, profit margins, and a revised future P/E multiple that together reshape their view of the stock's long term earnings power. Analyst Commentary While the higher price target reflects updated assumptions, bearish analysts are also flagging several risks that could limit upside if execution or market conditions do not line up with those assumptions.Anlatı Güncellemesi • Feb 24
ANIP: Higher 2026 Revenue Guidance Will Support Richer Forward P/E Multiple
Analysts have lifted their price target on ANI Pharmaceuticals by $9, reflecting updated assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Bullish Takeaways Bullish analysts view the US$9 price target increase as a sign that updated revenue assumptions support a higher valuation multiple on forward earnings.Anlatı Güncellemesi • Feb 10
ANIP: Higher 2026 Revenue Outlook And Refined P/E Framework Will Support Upside
Analysts have raised their price target on ANI Pharmaceuticals by about $1 to $110.50, citing updated views on revenue growth, profit margins, discount rate, and future P/E assumptions reflected in recent research. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$110.50 target as better aligned with updated assumptions on revenue and margins, suggesting the stock now reflects their latest fundamental work more closely.Anlatı Güncellemesi • Jan 26
ANIP: Future Outlook Will Balance Higher Guidance Expectations And Execution Risks
Analysts have raised their price target on ANI Pharmaceuticals by $9, citing updated expectations for revenue growth, profit margins, and a slightly lower future P/E as key drivers of their revised view. Analyst Commentary While the higher price target signals some confidence around updated revenue and margin expectations, bearish analysts are still flagging areas where the risk and reward profile may feel less attractive for new money.Anlatı Güncellemesi • Jan 12
ANIP: Raised Revenue Outlook And Pipeline Update Will Support Further Upside
Narrative Update on ANI Pharmaceuticals Analysts have trimmed their price target on ANI Pharmaceuticals to about $109.25 from roughly $109.88, citing updated assumptions around slightly higher revenue growth expectations, a modestly lower profit margin outlook, and a small adjustment in the forward P/E multiple. What’s in the News ANI Pharmaceuticals raised its full year 2025 net revenue guidance to a range of US$854 million to US$873 million, compared with prior guidance of US$818 million to US$843 million (Key Developments).Anlatı Güncellemesi • Dec 26
ANIP: Future Outlook Will Balance Corticotropin Momentum And Concentration Risks
Analysts have raised their price target on ANI Pharmaceuticals to $90 from $77, citing continued momentum from Cortrophin Gel, record Q2 sales of $82M, and a 20% full year guidance increase that supports expectations for sustained growth. Analyst Commentary Bearish analysts acknowledge that the higher $90 price target reflects recent strength, but they emphasize that the rating remains at Hold, signaling caution around near term upside.Anlatı Güncellemesi • Dec 12
ANIP: Future Outlook Balances Corticotropin Market Expansion And Competitive Uncertainties
Analysts have lifted their fair value estimate for ANI Pharmaceuticals to $90 from $77 per share as they factor in stronger than expected Cortrophin Gel momentum, higher sales visibility, and an expanding addressable market, despite slightly more conservative growth and margin assumptions. Analyst Commentary Recent Street research reflects a growing divide between optimistic expectations for Cortrophin Gel and a more cautious stance from bearish analysts who question the durability of current momentum and the stock's valuation profile.Anlatı Güncellemesi • Nov 26
ANIP: Continued Momentum Will Drive Upside as Market Opportunities Expand
Analysts have raised their price targets for ANI Pharmaceuticals, with increases ranging from $13 to $28 per share. They cite strong Cortrophin Gel sales momentum, expanded market opportunities, and resilient fundamentals as key factors driving the company’s continued growth outlook.Anlatı Güncellemesi • Nov 10
ANIP: Sustained Revenue Expansion Will Drive Momentum Amid Increasing Market Opportunities
Analysts have increased their average price target for ANI Pharmaceuticals from $105 to approximately $109.88, citing robust Cortrophin Gel performance, expanded market opportunities, and a strengthened revenue outlook. Analyst Commentary Industry analysts are closely monitoring ANI Pharmaceuticals following a series of price target increases.Anlatı Güncellemesi • Sep 25
Expanding ACTH Potential And Rare Disease Markets Will Evolve
ANI Pharmaceuticals’ price target was raised to $105.00 as analysts cite robust Cortrophin Gel prescription trends, a significantly expanded addressable market, and outstanding Q2 revenue growth. Analyst Commentary Bullish analysts highlight that Cortrophin Gel prescription data is consistently surpassing forecasts, indicating stronger-than-expected demand.Anlatı Güncellemesi • Aug 10
Expanding ACTH Potential And Rare Disease Markets Will Evolve
Despite a meaningful reduction in consensus revenue growth forecasts, ANI Pharmaceuticals’ future P/E multiple has declined, improving perceived value and contributing to an upward revision of the consensus analyst price target from $81.38 to $85.75. What's in the News ANI Pharmaceuticals raised 2025 earnings guidance to $818–$843 million from prior $768–$793 million.Analiz Makalesi • Aug 10
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Surges 25% Yet Its Low P/S Is No Reason For Excitement
NasdaqGM:ANIP 1 Year Share Price vs Fair Value Explore ANI Pharmaceuticals's Fair Values from the Community and select...Analiz Makalesi • Jun 21
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • May 16
We Think Shareholders Will Probably Be Generous With ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) CEO Compensation
Key Insights ANI Pharmaceuticals' Annual General Meeting to take place on 22nd of May Total pay for CEO Nikhil Lalwani...Analiz Makalesi • Mar 28
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Fly 25% But Investors Aren't Buying For Growth
ANI Pharmaceuticals, Inc. ( NASDAQ:ANIP ) shareholders have had their patience rewarded with a 25% share price jump in...Analiz Makalesi • Feb 25
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Feb 11
ANI Pharmaceuticals: More Than Just A Generics Company
Summary ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, and contract manufacturing. Despite cash burn concerns, ANI's revenue growth, strategic moves, and overlooked royalty streams indicate long-term value creation. ANI's rare disease asset, Purified Cortrophin Gel, and generics pipeline, including Prucalopride, position it for significant revenue growth and market re-rating. The company's debt restructuring and diversified revenue streams enhance financial stability, making it a potential buyout target in the specialty pharma sector. Read the full article on Seeking AlphaAnaliz Makalesi • Dec 18
ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Prospects Need A Boost To Lift Shares
You may think that with a price-to-sales (or "P/S") ratio of 2x ANI Pharmaceuticals, Inc. ( NASDAQ:ANIP ) is a stock...Analiz Makalesi • Nov 09
Here's Why ANI Pharmaceuticals (NASDAQ:ANIP) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Seeking Alpha • Nov 02
ANI Pharmaceuticals Is Acting Like It Is Being Acquired
Summary Several actions or omissions by ANIP is consistent with them being acquired and being restricted in what they can disclose. Offer could exceed $8 billion plus sales based CVRs. Offer likely contingent on FDA approval of NDA filed in Q3 2023 for undisclosed drug filed by ANIP but application appears to be financed by undisclosed partner. Read the full article on Seeking AlphaSeeking Alpha • Oct 11
ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market
Summary Today, we revisit small biopharma ANI Pharmaceuticals, as it is a GARP stock trading near technical support, with solid growth prospects. The company recently acquired Alimera Sciences for $380 million, boosting its rare disease segment with a couple of durable ophthalmology products. Analyst firms are generally bullish on the company's prospects and the stock trades at 12 times trailing earnings, despite revenue growth in the high teens. An analysis of ANIP follows in the paragraphs below. Read the full article on Seeking Alpha
Yeni Anlatı • Sep 15
Purified Cortrophin Gel And Strategic Acquisitions Propel Robust Revenue Surge In Rare Disease Sector
Accelerating demand for their lead Rare Disease asset and growth in generics, along with expanding sales efforts, are expected to significantly boost revenues.Analiz Makalesi • Sep 10
There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues
ANI Pharmaceuticals, Inc.'s ( NASDAQ:ANIP ) price-to-sales (or "P/S") ratio of 2.2x might make it look like a buy right...Analiz Makalesi • Aug 14
ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem
ANI Pharmaceuticals, Inc.'s ( NASDAQ:ANIP ) robust earnings report didn't manage to move the market for its stock. Our...Analiz Makalesi • Aug 08
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Aug 02
ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028
Summary ANIP has three 505(b)(2) NDA submissions under FDA review, including oral liquid terazosin, female testosterone drug, and oral liquid hydrochlorothiazide. Potential peak sales for Tezruly and hydrochlorothiazide in the US could exceed $500 million, while the female testosterone drug could generate $290 million in royalties. ANIP's revenue could reach $1.41 billion in sales and $290 million in royalties by 2028, with significant growth potential. Read the full article on Seeking AlphaAnaliz Makalesi • Jun 10
Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price
There wouldn't be many who think ANI Pharmaceuticals, Inc.'s ( NASDAQ:ANIP ) price-to-sales (or "P/S") ratio of 2.5x is...Seeking Alpha • Jun 10
ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked
Summary ANIP's potential royalty revenue from two upcoming drug applications could generate $415 million annually, not reflected in the current share price. ANI Pharmaceuticals' legal action against CG Oncology could result in royalties for Cretostimogene, potentially adding $125 million per year. The Company's female testosterone drug could generate royalties of $290 million per year, with potential for additional indications and international sales. Read the full article on Seeking AlphaHissedar Getirileri
| ANIP | US Pharmaceuticals | US Pazar | |
|---|---|---|---|
| 7D | -2.6% | -0.5% | 0.6% |
| 1Y | 26.7% | 45.8% | 19.5% |
Getiri vs. Endüstri: ANIP geçen yıl % 45.8 oranında getiri sağlayan US Pharmaceuticals sektörünün gerisinde kaldı.
Getiri vs Piyasa: ANIP geçen yıl % 19.5 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| ANIP volatility | |
|---|---|
| ANIP Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 9.2% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: ANIP son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: ANIP 'nin haftalık oynaklığı ( 4% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2001 | 970 | Nikhil Lalwani | www.anipharmaceuticals.com |
Bir biyofarmasötik şirketi olan ANI Pharmaceuticals, Inc. Amerika Birleşik Devletleri'nde ve uluslararası alanda markalı ve jenerik farmasötik ürünler geliştirmekte, üretmekte ve pazarlamaktadır. Şirket, ILUVIEN ve YUTIQ ürünlerinin yanı sıra enjektabllar, softgel kapsüller ve Cortrophin jel sunmaktadır. Ayrıca oral katı doz ürünler, yarı katılar, sıvılar, topikaller, kontrollü maddeler ve potent ürünler de üretmektedir.
ANI Pharmaceuticals, Inc. Temel Bilgiler Özeti
| ANIP temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$1.80b |
| Kazançlar(TTM) | US$83.94m |
| Gelir(TTM) | US$923.71m |
21.2x
F/K Oranı1.9x
P/S OranıANIP aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| ANIP gelir tablosu (TTM) | |
|---|---|
| Gelir | US$923.71m |
| Gelir Maliyeti | US$361.86m |
| Brüt Kâr | US$561.85m |
| Diğer Giderler | US$477.92m |
| Kazançlar | US$83.94m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 3.96 |
| Brüt Marj | 60.83% |
| Net Kâr Marjı | 9.09% |
| Borç/Özkaynak Oranı | 109.2% |
ANIP uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/09 20:26 |
| Gün Sonu Hisse Fiyatı | 2026/07/09 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
ANI Pharmaceuticals, Inc. 16 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Glen Santangelo | Barclays |
| Dewey Steadman | Canaccord Genuity |
| Timothy Chiang | Capital One Securities, Inc. |